We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Technology | Level of Detection | Strengths | Custom Products | |
---|---|---|---|---|
CDCAP NGS | Hybridization capture | DNA or RNA | -Enables detection of known and unknown fusion genes -Not requiring RNA purification, simplifying sample preparation and enhancing efficiency | Tailored Capture Panels (CDCAP) to suit your research needs and gene targets. Learn more. |
CDAMP NGS | Amplicon | DNA or RNA | - Lower RNA input required - Effective with small and mid-sized panels - Only anchored mPCR enables detection of known and unknown fusion gene events - 5' and 3' imbalance evaluation can increase test analytical accuracy | Custom Amplicon Panels (CDAMP) for specific fusion gene targets or regions of interest. Learn more. |
RNA Sequencing | NGS | RNA | Compatible with diverse RNA samples, including fresh, frozen, FFPE tissues, and liquid biopsies, accommodating various research scenarios | - Tailored RNA Sequencing for broader transcriptomic analysis - See our CD RNA Fusion Gene Panel |
PacBio Iso-Seq | Long-Read Sequencing | RNA | - Sequencing of full-length RNA transcripts, including fusion variants - Detailed characterization of alternative splicing events and complex fusion isoforms - Gene expression changes and post-transcriptional modifications | Customize your Iso-Seq experiments for specific fusion genes or alternative splicing studies |
Background
Identification of fusion genes is crucial for accurate diagnosis and treatment planning in various malignancies, including acute myeloid leukemia (AML). Traditionally, cytogenetics and targeted molecular genetics have been employed for fusion gene detection. However, the emergence of sequencing technologies offers the potential to enhance diagnostic accuracy and efficiency. This case study focuses on evaluating the performance of RNA-seq for fusion gene detection in AML patients, comparing it with standard diagnostic techniques.
Challenges
The conventional approaches for fusion gene detection have limitations, including time-consuming processes, restricted target coverage, and subjective interpretation. The challenge lies in assessing whether RNA-seq can provide a comprehensive and reliable alternative for fusion gene identification.
Methods
In this study, a total of 806 RNA-seq samples from patients with AML were analyzed using two advanced software tools: Arriba and FusionCatcher. The aim was to determine the efficacy of RNA sequencing in detecting fusion events compared to routine diagnostic methods. Samples that exhibited discrepancies in fusion gene detection were subjected to a systematic analysis of sequence coverage to identify potential underlying causes.
Detection workflow. (Kerbs et al., 2022)
Results
The most significant outcomes of the study included the discovery of 157 novel fusion gene candidates that demonstrated robust evidence. Comparisons with established fusion gene databases (ChimerDB and Mitelman Database) revealed the recurrence of novel fusion genes in 14 cases, showcasing the power of RNA-seq in uncovering new fusion events.
A particularly notable finding was the identification of the recurrent fusion gene NRIP1-MIR99AHG resulting from inv(21) (q11.2;q21.1) in nine patients and LTN1-MX1 resulting from inv(21)(q21.3;q22.3) in two patients. The study provided insights into the functional implications of the NRIP1-MIR99AHG fusion, including its role in overexpression of the 3' region of MIR99AHG and disruption of the tricistronic miRNA cluster miR-99a/let-7c/miR-125b-2. This mechanism is recognized in leukemogenesis, particularly in acute megakaryoblastic leukemia.
Detection and validation of the novel NRIP1-MIR99AHG fusion gene. (Kerbs et al., 2022)
Conclusion
The case study demonstrated that RNA-seq holds significant potential to revolutionize the systematic detection of fusion genes in clinical applications. By outperforming conventional techniques, RNA-seq provides a valuable tool for fusion gene discovery, contributing to more accurate diagnoses and improved patient care in conditions such as acute myeloid leukemia. The study's findings underscore the importance of integrating cutting-edge sequencing technologies into routine clinical practices to enhance diagnostic precision and advance our understanding of disease mechanisms.
Reference:
Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to info@cd-genomics.com for inquiries.
Please fill out the form below: ×